



## COMPANY FACTSHEET



# Phytoceuticals

Phytoceuticals is a life science company that develops innovative medicines from natural product extracts.

## STRATEGY

The company's current focus is to develop first-in-class solutions for major indications in dermatology. Upon receiving product registration, Phytoceuticals aims at partnering with a strong industry partner for product distribution in order to maximize the potential reach and revenue for the product.

## PIPELINE

Phytoceuticals' lead product, 1 PRIMARY WOUND DRESSING® is a primary wound dressing with comprehensive capabilities, targeting acute and chronic wounds in humans. In addition to the market for acute and chronic human wounds, formulations derived from Ⓞ are targeting the markets for veterinary wounds (PHY020) and human inflammatory skin disorders (PHY030).

## INTELLECTUAL PROPERTY

Ⓞ, PHY020 and PHY030 are based on a combination of natural extracts. The combination was granted a European patent in 2008. Phytoceuticals is currently seeking additional patent protection in all major countries.

## SIGNIFICANT UNMET CLINICAL NEED

In wound care, no single exogenous agent presently available can effectively mediate all of the numerous aspects of the wound healing process. Ⓞ is the simple, natural and effective first choice product for the treatment of acute and chronic wounds.

## FACTS AND FIGURES

### HEADQUARTER

Phytoceuticals Ltd.  
Zollikerstr. 44, 8008 Zurich,  
Switzerland  
[www.phytoceuticals.ch](http://www.phytoceuticals.ch)

### FOUNDED

December 2007

### OWNERSHIP

Privately held

### MAJOR INVESTOR

Bridgeworks AG  
Zurich, Switzerland

### INDUSTRY SECTOR

Life sciences

### INITIAL PRODUCT FOCUS

Medicines from natural product  
extracts targeting major  
indications in dermatology

### EMPLOYEES

6.5 FTE

### MEDIA CONTACT

Eduardo Theiler  
Phytoceuticals Ltd.  
+41 43 499 15 66

---

## LEADERSHIP TEAM

DR. STEPHAN RIETIKER, M.D.  
Chairman

EDUARDO THEILER  
Chief Executive Officer

DR. MARTIN MEILI, M.D.  
Director

KUNO JUNG, PHD  
Director

BEAT BUEHLMANN, PHD  
Director

Stephan Rietiker, M.D., is Chairman of Phytoceuticals. Dr. Rietiker is the former President and CEO of Sulzer Medica/CenterPulse; he is Chairman of his Switzerland-based investment platform AurigaVision AG, and Senior Advisor to Brown Brothers Harriman's Life Sciences practice. Eduardo Theiler, CEO of Phytoceuticals, devoted two years to investment banking before founding "go4equity", a European platform for private equity transactions. In 2004, he founded Bridgeworks, which incubates companies that devise bold and effective solutions to fundamental challenges of the future.

## SCIENTIFIC ADVISORY BOARD

---

DR. THOMAS HUNZIKER, M.D.

---

Professor of Dermatology  
University Hospital Bern, Department of Dermatology, Switzerland

---

DR. SEVERIN LAEUCHLI, M.D.

---

Dermatologist, Wound Specialist  
University Hospital Zurich, Department of Dermatology, Switzerland,  
President, Swiss Association for Woundcare

---

DR. RAINER GOERNE, M.D.

---

Pharmacologist and Toxicologist, Primary Care Physician, Germany

---

## PRODUCT DEVELOPMENT TIMELINE

Research | Proof-of-Concept | Development | Registration | Launch

---

ACUTE AND CHRONIC  
HUMAN WOUND CARE  
①



---

ACUTE AND CHRONIC  
VETERINARY WOUND CARE  
PHY020



---

## TESTIMONIALS

---

**Prof. Dr.**

**Thomas Hunziker, M.D.**

*Dermatologist*

*University Hospital Bern,  
Switzerland*

Ⓢ creates a moist wound environment. The oil layer prevents the secondary dressing from adhering to the wound. These are minimal requirements a modern wound product has to meet. Furthermore, Ⓢ has an antimicrobial effect and promotes the regeneration of the epidermis. These effects clearly make Ⓢ a modern and convincing wound product of your first choice.

---

**Dr. Severin Laeuchli, M.D.**

*Dermatologist*

*University Hospital Zurich,  
Switzerland*

Results in various types of acute and chronic wounds suggest that Ⓢ can be used as an effective primary wound dressing that promotes wound healing and protects the periwound skin. The use of Ⓢ led to an impressive induction of granulation tissue, even in very deep wounds. Ⓢ, with its simple treatment procedure, was very well accepted by patients since it facilitated painless removal of the secondary dressing. Ⓢ clearly has its finger on the pulse of understanding the cost and time pressure of the wound care industry.

---

**Dr. Stephan Rietiker, M.D.**

*Chairman Phytoceuticals Ltd.*

By merging Ⓢ into its portfolio, a strong pharmaceutical company that is new to the wound care industry would be able to establish its presence with a very innovative and unique product and fully capitalize on the potential of Ⓢ.